日本一个药品公司人工合成了一种新的降压物质。临床实验证明,它与以往降压药物相比,具有毒性小、副作用少的特点。在高血压症中占有相当一部分的肾性高血压的血管紧张素原很容易转变为血管紧张素Ⅱ,使血压上升。这种变化与两个阶段的酶反应有关,因此降压药的根本机能就是阻碍酶的作用。然而过去的药品不仅能阻碍与高血压有关的酶的作用,也能阻碍与高血压无关的酶的作用,所以具有一定的副作用。如今合成的这种称之为KRI-B14的新物质,是阻碍第一阶段反应所必需的酶肾素的作用,具有新的 A Japanese drug company artificial synthesis of a new antihypertensive substances. Clinical experiments show that compared with the previous antihypertensive drugs, with less toxicity, fewer side effects. Angiotensinogen, which accounts for a significant portion of hypertension in hypertension, is readily converted to angiotensin II, which increases blood pressure. This change and the two stages of the enzyme reaction, so the fundamental function of antihypertensive drugs is to hinder the role of enzymes. However, the past drugs not only hinder the role of hypertension-related enzymes, but also hinder the role of hypertension-independent enzymes, it has some side effects. The new substance now known as KRI-B14, which is synthesized, is an enzyme renin that blocks the first-stage reaction and has a new